Zynex Shares Plunge 36% Amid Q2 Revenue Growth and Board Shake-Up

Introduction

Zynex, Inc. (NASDAQ: ZYXI) is a Colorado-based medical device manufacturer specializing in non-invasive electrotherapy solutions for pain management, physical rehabilitation, neurological diagnosis, and cardiac monitoring. Founded in 1996 by Thomas Sandgaard, who currently serves as CEO, the company designs, manufactures, and markets its products through three operating subsidiaries: Zynex Medical, Zynex Monitoring Solutions, and Zynex NeuroDiagnostic.

Corporate Structure

Zynex operates out of Englewood, Colorado, under a holding structure that houses:

• Zynex Medical, which focuses on home-use TENS/IFC/NMES devices for pain relief and functional rehabilitation
• Zynex Monitoring Solutions, supplying non-invasive cardiac monitoring equipment to hospitals
• Zynex NeuroDiagnostic, dedicated to surface EMG and autonomic nervous system measurement tools

The company emphasizes service standards and field-based support teams to serve physicians, therapists, and direct-to-consumer channels.

Electrotherapy by Olga Kononenko

Developments and News

• On July 31, 2025, Zynex filed its Form 10-Q for the quarter ended June 30, 2025, outlining year-to-date revenue growth and operational trends, along with supply-chain mitigation efforts and ongoing FDA compliance initiatives.
• On July 29 and 31, 2025, Zynex submitted Form 8-K reports (Items 5.02, 2.02, and 9.01) disclosing changes to its board composition and governance policies, as well as amendments to its Code of Ethics.
• In February 2020, Zynex received FDA clearance for its CM-1500 Blood Volume Monitor, which expands its cardiac monitoring portfolio.
• A LinkedIn post dated July 2025 highlighted Zynex’s commitment to non-opioid pain solutions.

Financial and Strategic Analysis

As of August 1, 2025, Zynex shares traded at $1.42, down 36.32% from the prior close, on a volume of 549,047 shares. Key financial metrics (TTM) include:

• Revenue: approximately $172 million (Yahoo Finance) to $194 million (company IR), reflecting a 7% increase year-to-date
• Gross margin: approximately 80%
• Net income (TTM): –$7.4 million, resulting in a –4.3% profit margin
• EPS (TTM): –$0.24
• Cash on hand (MRQ): $23.9 million; total debt/equity: 351.6%
• Valuation multiples: Price/Sales 0.41; Price/Book 3.25; Enterprise value/revenue 0.68

Equity research assigns Zynex an Investment Rating of Sell, with a target price of $6.00, citing medium growth prospects alongside low financial strength and governance concerns. Strategic priorities include new product development in electrotherapy, market expansion through distributor partnerships, and cost-management initiatives to improve operating margins.

Market Position and Industry Context

Zynex competes in the global electrotherapy and non-invasive monitoring market alongside larger medical device OEMs and rehabilitation equipment specialists. Its devices serve as alternatives to opioid prescriptions and in-hospital monitoring regimes. Key industry challenges include:

• Changes in reimbursement policies for home health equipment
• Regulatory reviews by the FDA and equivalent agencies abroad
• The necessity for innovation, requiring ongoing R&D investment

The company's focus on outpatient therapy and home-use platforms aligns with a growing trend toward value-based care and reduced hospital stays.

tl;dr

On July 31, 2025, Zynex reported TTM revenue of $172 million to $194 million and a net loss of $7.4 million, with EPS of –$0.24 and gross margins near 80%. Shares fell 36% to $1.42 on August 1, 2025. Governance updates were filed via 8-K on July 29 and 31, 2025. Analysts rate the stock Sell with a $6.00 target. The next earnings release is scheduled for October 30, 2025.